Carmen Carr
Nurse Practitioner · Flowood, MSNPI 1679934624
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Akebia Therapeutics Inc accounts for 61.0% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2022 at $3,680 and has fallen 67.6% since, to $1,192 in 2025. Among nurse practitioner clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $44.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$4K
- Novartis$352
- Amgen$321
- Calliditas Therapeutics US Inc.$209
- Mallinckrodt Hospital Products Inc.$207
- OPKO Pharmaceuticals, LLC$204
- plus $1K from 18 others
What the payments were for
- Speaking & faculty fees$2,88046%
- Travel & lodging$3546%
- Food & beverage$2,80845%
- Education$2063%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 23 | $3,812 |
| Novartis | 14 | $352 |
| Amgen(2 entities) | 14 | $321 |
| Calliditas Therapeutics US Inc. | 9 | $209 |
| Mallinckrodt Hospital Products Inc. | 8 | $207 |
| OPKO Pharmaceuticals, LLC | 12 | $204 |
| AstraZeneca(2 entities) | 10 | $195 |
| Otsuka America Pharmaceutical, Inc. | 7 | $174 |
| Bayer | 8 | $161 |
| Fresenius USA Marketing, Inc. | 6 | $101 |
| Travere Therapeutics, Inc. | 7 | $86 |
| Aurinia Pharma U.S., Inc. | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 4 | $73 |
| Ardelyx, Inc. | 2 | $44 |
| Apellis Pharmaceuticals, Inc. | 2 | $36 |
| Vifor Pharma, Inc. | 1 | $32 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Genentech USA, Inc. | 1 | $25 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
| Novo Nordisk | 1 | $20 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $19 |
| GSK | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Boston Scientific | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AURYXIA$3,555
How this compares
$6,247 in reported general payments places this provider in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuryxiaFerric Citrate | 169 | $293,441 |
| VelphoroSucroferric Oxyhydroxide | 77 | $248,391 |
| XphozahTenapanor Hcl | 16 | $44,866 |
| Sevelamer Carbonate | 237 | $23,481 |
| EliquisApixaban | 13 | $16,689 |
| RayaldeeCalcifediol | 11 | $14,723 |
| Lanthanum Carbonate | 21 | $13,404 |
| OzempicSemaglutide | 13 | $12,385 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $9,507 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $8,025 |
| ProsolParenteral Amino Acid 20% No.1 | 34 | $6,085 |
| Calcium Acetate | 23 | $1,983 |
| Nifedipine ErNifedipine | 24 | $908 |
| Hydralazine Hcl | 47 | $672 |
| Furosemide | 90 | $460 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Akebia Therapeutics IncAuryxia | $3,812 | $293,441169 claims |
| Fresenius USA Marketing, Inc.Velphoro | $101 | $248,39177 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $204 | $14,72311 claims |
| Novo NordiskOzempic | $20 | $12,38513 claims |
| AstraZenecaLokelma | $195 | $8,02513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,090 nurse practitioner providers in Mississippi.
Other nurse practitioner in Flowood
- Sara KlausFlowood$48K
- Callie HallFlowood$7K
- Amanda SullivanFlowood$5K
- Christina TreppendahlRidgeland$125K
- Jo Anna WarrenJackson$73K
- Marisa StringerBiloxi$68K
- Micaela PerkinsOxford$32K
- Michelle TharpJackson$28K
- Kaylon LewisHattiesburg$25K
- Jennifer HollyJackson$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.